Yvan Jamilloux1–3,*
Mathieu Gerfaud-Valentin1,*
Thomas Henry3
Pascal Sève1
1Department of Internal Medicine, Hôpital de la Croix-Rousse, Université Claude Bernard-Lyon 1, Lyon, France; 2Department of Biochemistry, University of Lausanne, Epalinges, Switzerland; 3International Research Center on Infectiology, INSERM U1111. Université Claude Bernard Lyon-1, Lyon, France
*These authors contributed equally to this work

Abstract: Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that has been recently classified as a polygenic autoinflammatory disorder. The former classification, based on the disease course, seems to be quite dated. Indeed, there is accumulating evidence that AOSD can be divided into two distinct phenotypes based on cytokine profile, clinical presentation, and outcome, ie, a “systemic” pattern and an “articular” pattern. The first part of this review deals with the treatments that are currently available for AOSD. We then present the different strategies based on the characteristics of the disease according to clinical presentation. To do so, we focus on the two subsets of the disease. Finally, we discuss the management of life-threatening complications of AOSD, along with the therapeutic options during pregnancy.

Keywords: adult-onset Still’s disease, treatment, anakinra, tocilizumab, canakinumab

Introduction
Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder characterized by the classical triad of daily spiking fever, arthritis, and typical salmon-colored rash. It was first described in 1971 by Bywaters, who defined the disease on the basis of clinical and laboratory resemblance to juvenile Still’s disease.1 Indeed, in 1897, George Frederic Still had described 22 children with what is now called systemic-onset idiopathic juvenile arthritis (JIA).2,3 Whether AOSD and systemic-onset JIA belong to the same continuum of disease is still debated, but the evidence strongly suggests that AOSD and systemic-onset JIA are the same disease.4–6

The epidemiology, diagnostic criteria7–8 (Table 1), and classification of AOSD have been reviewed recently.9,10 The pathophysiology of AOSD remains obscure, and identification of an etiologic trigger is still lacking.

Over the last decade, one striking event was the reclassification of AOSD as a polygenic autoinflammatory disorder.11,12 This has mainly been deduced from demonstration of the pivotal role of innate immune pathways, mostly those involved in the processing of two cytokines of the interleukin (IL)-1 family (namely, IL-1β and IL-18). Other cytokines, such as IL-6 and to a lesser extent tumor necrosis factor alpha (TNF-α), are also involved in the pathogenesis of AOSD. Data from genetic and immunologic studies, together with the dramatic effect of biologic treatments, have confirmed the major role of these cytokines. Recently, there has been accumulating evidence that AOSD can be divided into two distinct phenotypes based on cytokine profile, clinical presentation, and outcome.10,13–15 These are discussed in this review.

The renewed comprehension of the disease, along with the availability of new cytokine inhibitors, has led to new therapeutic approaches. The general aim of this review is to discuss the optimal management of AOSD. The first part deals with the treatments that are currently available for AOSD. We then present the different strategies based on characteristics of the disease according to clinical presentation.
However, positive results remain associated with splenomegaly, low glycosylated ferritin, an occurrence in approximately 45% of cases. and has been associated with some biologics should be used earlier in the course of the disease, regardless of the clinical presentation. Nevertheless, studies of systemic-onset JIA are providing evidence that targeted biologic therapies (such as anakinra or tocilizumab) are possible alternatives, which could be used for a steroid-sparing effect. Methotrexate can lead to complete remission in up to 70% of patients and corticosteroid weaning has also been reported in some cases. However, positive results remain exceptional and these agents cannot be recommended unless severe complications occur and other more specific drugs have failed.

In contrast, methotrexate has proved beneficial and remains the first-line steroid-sparing treatment in AOSD. As for systemic-onset JIA, targeted biologic therapies (such as anakinra or tocilizumab) are possible alternatives, which could be used for a steroid-sparing effect. Methotrexate can lead to complete remission in up to 70% of patients and corticosteroid weaning has also been reported in some cases. Liver enzyme abnormalities do not contraindicate its prescription but require close biological monitoring.

Data concerning intravenous immunoglobulin are more controversial, with two randomized open-label trials showing some efficacy when used early in the course of AOSD, whereas retrospective data do not support the efficacy of intravenous immunoglobulin in AOSD. Overall, intravenous immunoglobulin has only a suspensive effect but is well tolerated. Thus, it should be considered in the event of reactive hemophagocytic lymphohistiocytosis (RHL; formerly known as macrophage activation syndrome), in some life-threatening complications, or in case of AOSD flare-up occurring during pregnancy. The usual dosage is 2 g/kg body weight administered in 2–5 days.

**Available treatments**

Given that the current information on treatment efficacy is obtained from small retrospective case series and not from prospective, double-blind, randomized trials, the treatment of AOSD remains empirical. In contrast, due to a higher prevalence, more data are available for systemic-onset JIA and will be discussed briefly. Recently, the management of AOSD has benefited from proofs of the efficacy of targeted biotherapies.

**Nonsteroidal anti-inflammatory drugs and corticosteroids**

Regarding available data on AOSD, the risk/benefit ratio is not favorable with regard to nonsteroidal anti-inflammatory drugs (NSAIDs). Indeed, more than 80% of AOSD patients did not achieve remission with NSAIDs and approximately 20% suffered adverse events. Nevertheless, temporary use of NSAIDs can be considered during diagnostic workup or for early relapse of the disease.

Corticosteroids remain the first-line treatment for AOSD, regardless of the clinical presentation. Nevertheless, studies of systemic-onset JIA are providing evidence that some biologics should be used earlier in the course of the disease. In addition, new treatment plans for systemic-onset JIA have placed methotrexate, anakinra, and tocilizumab as possible first-line treatments. Corticosteroids control about 60% of patients and show greater efficacy with regard to systemic symptoms than articular ones. Steroid dependency occurs in approximately 45% of cases. and has been associated with splenomegaly, low glycosylated ferritin, an elevated erythrocyte sedimentation rate, and young age at onset of AOSD. Thus, early addition of a steroid-sparing agent may be considered in patients who meet these criteria.

**Disease-modifying antirheumatic drugs and intravenous immunoglobulin**

In the event of failure of corticosteroid treatment or steroid-dependence, disease-modifying anti-rheumatic drugs (DMARDs) can be considered. Some retrospective case series and case reports have reported the efficacy of several DMARDs, such as cyclosporine A, leflunomide, azathioprine, hydroxychloroquine, D-penicillamine, and tacrolimus. However, positive results remain exceptional and these agents cannot be recommended unless severe complications occur and other more specific drugs have failed.

In contrast, methotrexate has proved beneficial and remains the first-line steroid-sparing treatment in AOSD. As for systemic-onset JIA, targeted biologic therapies (such as anakinra or tocilizumab) are possible alternatives, which could be used for a steroid-sparing effect. Methotrexate can lead to complete remission in up to 70% of patients and corticosteroid weaning has also been reported in some cases. Liver enzyme abnormalities do not contraindicate its prescription but require close biological monitoring.

Data concerning intravenous immunoglobulin are more controversial, with two randomized open-label trials showing some efficacy when used early in the course of AOSD, whereas retrospective data do not support the efficacy of intravenous immunoglobulin in AOSD. Overall, intravenous immunoglobulin has only a suspensive effect but is well tolerated. Thus, it should be considered in the event of reactive hemophagocytic lymphohistiocytosis (RHL; formerly known as macrophage activation syndrome), in some life-threatening complications, or in case of AOSD flare-up occurring during pregnancy. The usual dosage is 2 g/kg body weight administered in 2–5 days.

**Targeted biologic therapies**

Although dramatic responses have been reported in systemic-onset JIA when given as first-line treatment, targeted biologic agents are actually reserved for refractory AOSD. Resistance to first-line corticosteroids and second-line DMARDs defines refractory AOSD, which mostly includes the polycyclic or chronic courses of the disease.

**Table 1 Criteria for the diagnosis of adult-onset Still's disease**

| Major criteria | Fever $\geq 38.5^\circ C$ lasting $\geq 1$ week |
| Minor criteria | Arthralgia or arthritis lasting $\geq 2$ weeks |
| | Typical nonpruritic salmon-colored rash |
| | Leukocytosis $\geq 10,000/\text{mm}^3$ with granulocytes $\geq 80\%$ |
| | Sore throat |
| | Lymphadenopathy |
| | Splenomegaly |
| | Abnormal liver function tests |
| | Negative tests for antinuclear antibody and rheumatoid factor |
| Exclusion criteria | Infection |
| | Malignancy |
| | Other rheumatic disease (vasculitis) |

**Notes:** Diagnosis of adult-onset Still’s disease if $\geq 5$ criteria are present with $\geq 2$ being major criteria and no exclusion criteria. Data from.
Table 2 Review of previous use of biologic agents for refractory adult-onset Still’s disease

<table>
<thead>
<tr>
<th>Biologic agent</th>
<th>Reference</th>
<th>Cases (n)</th>
<th>AOSD subtype</th>
<th>Complete remission (%)</th>
<th>Partial remission (%)</th>
<th>Corticosteroid weaning (%)</th>
<th>Infections (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etanercept</td>
<td>Husni et al.⁴⁸</td>
<td>12</td>
<td>Articular</td>
<td>0</td>
<td>58</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Cavagna et al.⁴⁹</td>
<td>3</td>
<td>Articular</td>
<td>0</td>
<td>67</td>
<td>NR</td>
<td>0</td>
</tr>
<tr>
<td>Kraetsch et al.⁵⁰</td>
<td>6</td>
<td>Both</td>
<td>67</td>
<td>33</td>
<td>NR</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Kokkinos et al.⁴¹</td>
<td>4</td>
<td>Both</td>
<td>100</td>
<td>0</td>
<td>25</td>
<td>NR</td>
<td>0</td>
</tr>
<tr>
<td>Etanercept and infliximab</td>
<td>Fautrel et al.⁴²</td>
<td>20</td>
<td>Articular</td>
<td>25</td>
<td>55</td>
<td>NR</td>
<td>2</td>
</tr>
<tr>
<td>Anakinra</td>
<td>Fitzgerald et al.⁴⁷</td>
<td>4</td>
<td>Systemic</td>
<td>75</td>
<td>25</td>
<td>75</td>
<td>1</td>
</tr>
<tr>
<td>Kalliolias et al.⁴⁸</td>
<td>4</td>
<td>Systemic</td>
<td>25</td>
<td>75</td>
<td>75</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Kötter et al.⁴⁹</td>
<td>4</td>
<td>Both</td>
<td>100</td>
<td>0</td>
<td>NR</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Lequerré et al.⁵⁰</td>
<td>15</td>
<td>Both</td>
<td>64</td>
<td>87</td>
<td>13</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Laskari et al.⁵¹</td>
<td>25</td>
<td>Both</td>
<td>84</td>
<td>12</td>
<td>48</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Nordström et al.⁵²</td>
<td>12</td>
<td>Both</td>
<td>50</td>
<td>NR</td>
<td>25</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Giampietro et al.⁵³</td>
<td>28</td>
<td>Both</td>
<td>43</td>
<td>14</td>
<td>NR</td>
<td>NR</td>
<td>0</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>Puéchal et al.⁵⁴</td>
<td>14</td>
<td>Articular</td>
<td>57</td>
<td>7</td>
<td>NR</td>
<td>0</td>
</tr>
<tr>
<td>Cipriani et al.⁵⁵</td>
<td>11</td>
<td>Both</td>
<td>82</td>
<td>18</td>
<td>8</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Elkayam et al.⁵⁶</td>
<td>15</td>
<td>Articular</td>
<td>80</td>
<td>13</td>
<td>9</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviations: AOSD, adult-onset Still’s disease; NR, not reported.

Data concerning biologic agents used in AOSD are summarized in Table 2.

Anti-TNF-α

Historically, anti-TNF therapy was the first biologic therapy that was used to treat refractory AOSD. The administration schemes were based on those used in the treatment of rheumatoid arthritis. The three anti-TNF-α agents (ie, infliximab, etanercept, and adalimumab) have been used to treat refractory AOSD but data on adalimumab are limited to a few cases.²⁶ Data from case reports, retrospective case series, and one prospective open-label prospective trial are available. Complete remissions have been observed³⁷–⁴¹ but anti-TNF therapy was rather disappointing, mostly for systemic symptoms.²⁵ Switching from one molecule to another had no additional effect.¹⁶,⁴² Moreover, two patients who were started on etanercept and adalimumab developed RHL that could be linked with initiation of the treatment.⁴³–⁴⁵ Overall, TNF-α blockers seem to be of interest only for the treatment of chronic polyarticular disease.¹⁶,¹⁷,²³,²⁵ In that case, based on our experience and on analysis of the literature, infliximab should be the preferred molecule because of better efficacy. However, no prospective evidence sustains this preferred option, and each case should be carefully evaluated by AOSD experts before therapeutic changes.

IL-1 antagonists

Three IL-1 antagonists are presently available, ie, a recombinant antagonist of the IL-1 receptor (IL-1Ra, anakinra), a human monoclonal antibody directed against IL-1β (canakinumab), and a soluble IL-1 trap fusion protein (rilonacept). Anakinra has been more frequently reported in the treatment of AOSD.³⁵,⁴⁶–⁵²

The efficacy of anakinra has been reported in retrospective case series³⁵,⁴⁶–⁵¹ and in one prospective, randomized, open-label trial.⁵² Anakinra is particularly efficient in the rapid relief of systemic symptoms. Its effect on articular symptoms is less frequently reported. In almost all cases, inflammatory markers reverted to normal within about 2 weeks and corticosteroids could be tapered and discontinued. However, the effect of anakinra was suspensive, and relapses occurred frequently as soon as the treatment was stopped. In some cases, progressive dose reduction has enabled the weaning of anakinra. In the event of an insufficient response to anakinra, rilonacept and canakinumab can be considered because they have longer half-lives and can be administered every week or every 8 weeks, respectively. Indeed, both agents have been reported to be efficient in AOSD.⁵³–⁵⁶

More data are available in the setting of systemic-onset JIA.¹⁹,²⁰,²⁶,⁵⁵–⁵⁸ Swart et al reviewed the literature and reported on 140 children with systemic-onset JIA treated with anakinra.⁵⁷ Systemic symptoms resolved in 98% of the patients who had such symptoms. Fatigue and well-being improved in 93% of cases. Arthritis improved in 66% of the cases within a longer time (few months).

Complete disease remission was mostly observed in patients with systemic symptoms, less arthritis, and a shorter
duration of disease. Adverse events were most frequently pain and erythema at the injection site. More serious adverse events were rare (occurring in eight cases). Quartier et al confirmed the efficacy of anakinra in systemic-onset JIA by performing a multicenter, randomized, placebo-controlled clinical trial. The study included 24 patients with a systemic-onset JIA duration of more than 6 months and steroid dependency. After one month, anakinra had been effective in 8/12 patients (versus one in the placebo group) who reached the modified American College of Rheumatology Pediatric 30 score. At month 2, 9/10 patients in the placebo group who had been switched to anakinra were also responders. However, during the following open-label treatment period, a loss of response was observed over time and no patient achieved inactive disease.

Nigrovic et al reported on 46 patients who received anakinra as first-line treatment. Rapid resolution of systemic symptoms was observed in more than 95% of cases, along with an additional preventive effect on refractory arthritis in almost 90% of the patients. Notably, 60% of the patients achieved inactive disease. Based on these results, Nigrovic postulated that there could be a “window of opportunity” for IL-1 blockade if given at the very beginning of the disease (ie, within 6 months after onset). In Nigrovic’s model, systemic-onset JIA/AOSD would have a biphasic pattern. The first phase, being febrile and inflammatory, involves innate immunity, and evolves to an afebrile phase with chronic destructive arthritis involving adaptive immunity. This hypothesis has been somewhat reinforced by the results reported by Vastert et al in 2014. Indeed, they reported on a prospective series of 20 patients who received anakinra as first-line therapy. Eighty-five percent of the patients showed an American College of Rheumatology Pediatric 90 score response or had inactive disease within 3 months. Overall, 75% of the patients treated with anakinra alone achieved inactive disease. Although it is difficult to evaluate to what extent children with new-onset systemic-onset JIA enrolled in that study would have underwent monocylic course (ie disease that never relapses), these dramatic results clearly indicate that IL-1 blockade has an early place in the treatment strategy.

Tocilizumab

Tocilizumab is a humanized monoclonal antibody directed against the IL-6 receptor that has shown positive results in patients with refractory AOSD from several case series. Results from randomized placebo-controlled trials are available in systemic-onset JIA but not in AOSD. Generally, the patients responded rapidly and experienced a sustained clinical remission over time. Moreover, the effect of tocilizumab persisted for ≥6 months after its discontinuation. Tocilizumab seems to have a similar beneficial effect on the systemic and articular features of AOSD, has a marked corticosteroid-sparing effect, and has a good safety and tolerance profile. Indeed, in a recent retrospective series, only two cases among 34 tocilizumab-treated patients with AOSD had to withdraw from treatment due to severe infections. Other side effects were mild leukopenia or neutropenia, elevation of hepatic enzymes, hypercholesterolemia, and headache associated with tocilizumab infusion.

Optimal management of AOSD

Since the management of AOSD varies widely depending on the various clinical presentations of the disease, the optimal management is discussed in the second part of this review. A management algorithm is provided in Figure 1.

Nonrefractory AOSD

According to the abovementioned definition, nonrefractory AOSD corresponds to disease patterns that can be cured by using first-line corticosteroids ± methotrexate. This mostly includes the monocyclic and polycyclic courses of the disease, when corticosteroid dependency can be overcome with a first-line steroid-sparing agent. NSAIDs can be used during the diagnostic workup, in case of a monocyclic course of AOSD without major systemic or articular involvement or in case of isolated mild articular involvement. In such cases, the preferred NSAID is high-dose indomethacin (150–200 mg/day).

Corticosteroids should be started promptly once the diagnosis is confirmed. Usually, corticosteroid therapy starts at a dosage of 0.5–1 mg/kg/day, but an intravenous pulse of high-dose methylprednisolone can be used, particularly where there is severe visceral involvement. Higher dosages seem to be more efficient in controlling the disease, achieving remission earlier, and decreasing the number of relapses. Fractionated daily intakes of corticosteroids have also provided interesting results in insufficiently controlled patients. The response to corticosteroids should be obtained within hours or days. Usually, the tapering of corticosteroids can start after 4–6 weeks, when symptoms have resolved and biological parameters have returned to normal.

If patients show early signs of corticosteroid dependency or have the previously mentioned risk factors (splenomegaly,
Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.191.40.80 on 07-Jul-2017
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.191.40.80 on 07-Jul-2017
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Management of adult-onset Still’s disease

Low glycosylated ferritin, elevated erythrocyte sedimentation rate, or young age at AOSD onset, methotrexate could be considered early for its steroid-sparing effect. Usually, methotrexate (7.5–20 mg/week) enables complete remission of the disease (70%) or at least a significant reduction of daily corticosteroid intake. Methotrexate has a similar effect on systemic and arthritic AOSD. Blood count, renal function, and liver enzymes should be monitored before initiation of methotrexate and then every 1–2 months. If methotrexate fails to control the disease, other DMARDs could be considered. However, growing evidence suggests using targeted biologic therapies as early second-line treatment.

Refractory AOSD

It is becoming increasingly apparent that AOSD patients fall into two distinct subsets, ie, those presenting with systemic features and those presenting with prominent arthritis. These findings are supported by molecular evidence, cytokine profiles, clinical course, and response to treatment (Figure 2). In AOSD, such as in systemic-onset JIA, it remains unclear whether the two subsets of the disease are temporally related (biphasic disease) or present since the disease onset.

Predictive factors for a prominent articular pattern include female sex, proximal arthritis at disease onset, thrombocytosis, and corticosteroid dependency, whereas high fever, high levels of liver enzymes, or high acute phase reactants are more likely to be associated with a systemic pattern of AOSD. Other clues to identify the systemic subtype of AOSD are the following: thrombocytopenia, RHL, and hyperferritinemia. Although the cytokine dosage is not performed in routine care, IL-18, interferon-γ, IL-10, and IL-4 are associated with systemic AOSD whereas IL-6, IL-17, and IL-23 are associated with arthritic AOSD.

This dichotomy may be of the utmost importance for the management of AOSD patients, as patients falling into one of the two categories should benefit from different treatments.
Patients with systemic AOSD are more likely to be responders to first-line corticosteroid therapy. In the case of refractory systemic AOSD, IL-1 antagonists (mostly anakinra) should be considered first as they have proved to be dramatically more efficient for systemic symptoms than for articular features. Anakinra is used at 100 mg/day via subcutaneous injection. Once the disease is controlled and the biological parameters have returned to normal, subcutaneous injections can be spaced. The most commonly reported adverse event with anakinra has been self-limiting erythema at the injection site. Unlike anakinra, anti-TNF-α agents usually have a less sustained effect on systemic symptoms.

Tocilizumab should be considered as an alternative to IL-1 antagonists, particularly when articular signs such as joint erosion accompany systemic symptoms. Nevertheless, tocilizumab has been less widely used in treating AOSD and should actually be used only if anti-IL-1 treatments fail to control the disease or if relapses occur during weaning of anti-IL-1. Tocilizumab is given at a dosage of 5–8 mg/kg body weight every 2–4 weeks. Nevertheless, larger randomized studies are still needed to further determine the optimal therapeutic scheme for tocilizumab.

In patients with articular refractory AOSD, anti-TNF-α should be the preferred treatment. Infliximab, given with a therapeutic scheme similar to that used for rheumatoid arthritis (ie, 3–5 mg/kg at weeks 0, 2, and 6, and then once every 8 weeks), seems to have better efficacy than etanercept, but larger studies are required to compare these two molecules. Since available data on the efficacy of adalimumab in AOSD are lacking, it cannot be recommended so far. In the case of failure of anti-TNF-α, tocilizumab should be considered first as it has proven efficient for both the articular and systemic features of AOSD. If tocilizumab fails, anakinra may be tried.

Finally, it should be noted that, in an effort to standardize therapeutic management and evaluate comparative effectiveness in an observational setting, the Childhood Arthritis and Rheumatology Research Alliance has developed four...
consensus treatment plans for systemic-onset JIA. These plans include a glucocorticoid plan, a methotrexate plan, an anakinra plan, and a tocilizumab plan. As no guidelines are available for AOSD, this consensus plan should be of help for physicians dealing with new-onset AOSD.

**Life-threatening complications of AOSD**

**Reactive hemophagocytic lymphohistiocytosis**

RHL corresponds to an uncontrollable activation of the reticuloendothelial system leading to phagocytosis of hematopoietic cells by activated tissue macrophages. In AOSD, RHL has been reported to have an incidence of 12%–17%.79–81 Evidence for occult RHL in a substantial proportion of patients with AOSD (up to 50%) supports the possibility that RHL and AOSD could represent the same disease within a continuum of severity.82,83 Considering all the underlying causes, the mortality rate for RHL ranges between 10% and 22%.84–86 The clinical picture and diagnostic criteria are presented in Table 3.81 Although RHL features resemble those of AOSD, differences exist and may help the early recognition of RHL during AOSD,85 the fever pattern is mostly non-remitting in RHL; there are less central nervous system involvement and hepatosplenomegaly during AOSD flare-ups than during RHL; and neutrophil and platelet counts are elevated in AOSD whereas they are low in RHL. Notably, a rapid decrease in leukocyte count or the rapid appearance of an hypertriglycerideridemia may alert the physician on the onset of RHL complicating previously diagnosed AOSD. Hypofibrinogenemia is also one of the most important clues indicating RHL, since AOSD patients are more likely to have hypofibrinogenemia due to the underlying inflammatory state. Hyperferritinemias is difficult to interpret in an AOSD patient because an acute increase in total and glycosylated serum ferritin can indicate a flare-up of AOSD or RHL. Bone marrow aspiration is the gold standard for diagnosis of RHL. It is not to be performed systematically but can be required in atypical cases and when there is a diagnostic dilemma.

Treatment of RHL in AOSD patients has mostly been empirical and has consisted of intravenous pulsed corticosteroids or intravenous immunoglobulin.88 Several immunosuppressive drugs have also been used, including cyclosporine A, mycophenolate mofetil, or etoposide.83,87 More recently, several authors have reported on the successful management of RHL complicating adult or pediatric Still’s disease using IL-1 antagonists.88–91 It is possible that higher doses of anakinra are required to treat Still’s disease-associated RHL (ie, 100 mg/6 hours).89 On the contrary, anti-TNF-α has proven ineffective or even harmful in treating RHL. Yet, several cases of RHL associated with etanercept have been reported in patients with AOSD.88,92 Finally, tocilizumab has been reported to be effective in the management of AOSD-related RHL, but these preliminary results still need to be confirmed.93

**Disseminated intravascular coagulopathy**

Disseminated intravascular coagulopathy (DIC) is characterized by an unregulated overactivation of the coagulation system. Fewer than ten cases have been reported in the setting of AOSD.81 However, the diagnosis can be challenging since the clinical picture may mimic sepsis and DIC may complicate AOSD-related RHL.94–96 The reported efficient treatments of AOSD-associated DIC include prednisolone,97 cyclosporine A,96–98 anakinra,49 and tocilizumab.99 So far, since only few data are available, it is not possible to recommend one or another molecule. Nevertheless, taking into account the morbidity of DIC, it seems reasonable to propose early therapy with anti-IL-1 or anti-IL-6 to AOSD patients who do not respond rapidly to corticosteroids.96,98

**Myocarditis**

We recently described four previously unreported cases of AOSD-related myocarditis and reviewed 20 other cases from the literature (Gerfaud-Valentin et al Medicine69). Myocarditis was an early life-threatening complication of AOSD occurring within the first year after the disease onset and affecting younger patients, mostly males. All the patients were given high-dose corticosteroids (either intravenous pulses or 1 mg/kg body weight). Intravenous immunoglobulins were added in 6/24 patients, methotrexate

---

**Table 3 Diagnostic criteria for hemophagocytic lymphohistiocytosis**

<table>
<thead>
<tr>
<th>Laboratory criteria</th>
<th>Clinical criteria</th>
<th>Histopathological criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased platelet count</td>
<td>Central nervous system dysfunction</td>
<td>Evidence of macrophage hemophagocytosis in bone marrow aspirate</td>
</tr>
<tr>
<td>Elevated levels of aspartate aminotransferase</td>
<td>Hemorrhages</td>
<td></td>
</tr>
<tr>
<td>Decreased white blood cell count</td>
<td>Hepatomegaly</td>
<td></td>
</tr>
<tr>
<td>Hypofibrinogenemia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Positive diagnosis requires two or more laboratory criteria or two or more clinical and/or laboratory criteria. Bone marrow aspiration may be required in doubtful cases. Data from.96
In the subset of women without previously known AOSD, we recently reviewed the link between AOSD and pregnancy. AOSD and pregnancy or intravenous cyclophosphamide. Therapeutic options include an intravenous pulse of high-dose methylprednisolone (1 g/day for 5 days), plasma exchange, or intravenous immunoglobulin seems to be useful and methotrexate steroid-sparing.

**Thrombotic thrombocytopenia purpura**

About ten cases of AOSD-related thrombotic thrombocytopenic purpura (TTP) have been reported. The pathophysiologic link between TTP and AOSD remains unknown. The clinical sign that should alert the clinician is acute visual loss. Early detection of TTP is required because it is associated with high morbidity and mortality. Delayed treatment of TTP may lead to renal failure, brain edema, and death. Thrombocytopenia and unexplained microangiopathic hemolytic anemia are arguments for a diagnosis of TTP during AOSD. Plasma exchange is always required in the event of AOSD-associated TTP. Additional drugs have been used with success, such as corticosteroids, intravenous immunoglobulin, azathioprine, cyclophosphamide, or rituximab. Only one author has reported on successful treatment of AOSD-related TTP using tocilizumab, which seemed to be efficient in treating both TTP and the underlying refractory AOSD.

**Diffuse alveolar hemorrhage**

Diffuse alveolar hemorrhage is a rare life-threatening complication of AOSD characterized by accumulation of erythrocytes in the lung alveolar spaces. Whether diffuse alveolar hemorrhage is a specific complication of AOSD or is coincidental remains unclear. Clinicians should think about diffuse alveolar hemorrhage when AOSD patients present with hemoptysis, cough, and dyspnea progressing to respiratory distress, together with falling hematocrit and hemorrhagic bronchoalveolar lavage fluid. Therapeutic options include an intravenous pulse of high-dose methylprednisolone (1 g/day for 5 days), plasma exchange, or intravenous cyclophosphamide.

**AOSD and pregnancy**

We recently reviewed the link between AOSD and pregnancy. In the subset of women without previously known AOSD, the disease occurred mainly during the first or second trimester. Due to flares, some cases were complicated by oligohydramnios or prematurity. No life-threatening complications were reported. In the second subset of women with known AOSD, flares were less frequent and more likely to occur during the second trimester and the postpartum period. Of note, data concerning preventive treatment are controversial and do not allow guidelines or recommendations. Treatment of AOSD flares during pregnancy always included prednisone at a dosage of 0.5–1 mg/kg body weight. The safety of corticosteroids has been established for usual dosages, but their effect at higher dosages remains unclear. In our previous article, it was not possible to state whether obstetric complications were due to the treatment or to the underlying disease. Thus, multidisciplinary expertise is required when corticosteroids are required. In some cases, intravenous immunoglobulins has been added but their effect on the outcome cannot be clearly determined. Although NSAIDs have been used, they are not recommended during pregnancy, particularly after week 24. Anakinra was used during three pregnancies in patients with AOSD. Both the outcome of the AOSD and the pregnancies were positive. The disease was controlled in all three cases and the children were born at term and healthy. Finally, close multidisciplinary monitoring before, during, and after pregnancy is required for women with AOSD.

**Conclusion**

Adult-onset Still’s disease is a complex disease with a polymorphic clinical presentation. In some cases, AOSD is as simple as a unique flare easily cured by NSAIDs or short-course corticosteroid therapy. On another hand, AOSD can present with stormy systemic features and lead to life-threatening complications (such as RHL) or as a chronic articular disease that may be either indolent or destructive. Recent advances in our understanding of the pathophysiology of AOSD and the availability of anti-cytokine-targeted treatments have given rise to more personalized treatments. In the near future, understanding of AOSD will probably benefit further from wide genetic analyses. Targeted biologic therapies seem to have a dramatic effect when given as frontline treatment in systemic-onset JIA. Results from ongoing observational studies and future prospective trials may lead to the recommendation of earlier use of these treatments in AOSD. Finally, the management of AOSD will also benefit from the release of new targeted biotherapies, such as anti-IL-18 or anti-IL-17.
Acknowledgments

YJ acknowledges the Foundation for the Development of Internal Medicine in Europe, the Société Nationale Française de Médecine Interne, Groupama Foundation, and Genzyme for their help in funding his PhD research project. YJ is supported by a “poste d’accueil” at INSERM.

Disclosure

The authors report no conflicts of interest in this work.

References


